Search results
Duchenne Muscular Dystrophy (DMD) Treatment
Verywell Health via Yahoo News· 4 days agoInsights Into Treatment Advancements Medically reviewed by Nicholas R. Metrus, MDMedically reviewed by Nicholas R. Metrus, MD Duchenne muscular
Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again
Investor's Business Daily· 2 days agoDyne studied drugs it calls DYNE-101 and DYNE-251 in patients with myotonic dystrophy type 1 and ...
European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug
BioPharma Dive via Yahoo Finance· 2 days agoRather than endorse the recommendation of the EMA, the commission called for a new review for...
Jar of Hope staging unique race to save kids
Staten Island Advance· 7 days agoAll proceeds will go toward funding a cure for Duchenne muscular dystrophy. “We’ve taken great pains to plan unique events over the years ...
Barclays cuts Solid Biosciences target to $18 from $21 By Investing.com
Investing.com· 6 days agoOn Thursday, Barclays adjusted its outlook on Solid Biosciences (NASDAQ:SLDB), a company...
Biotech Soars As Its Biggest Drug 'Lives To Fight Another Day'
Investor's Business Daily· 2 days agoTranslarna has a conditional approval in Europe to treat patients with a muscle-wasting disease...
Dyne shares jump on trial data for muscle disease drugs
BioPharma Dive via Yahoo Finance· 2 days agoUpdated study results for the biotech’s medicines for myotonic dystrophy Type 1 and Duchenne ...
Why Is Dyne Therapeutics Stock Soaring On Monday?
Benzinga via Yahoo Finance· 2 days agoEarlier this year, Dyne Therapeutics released initial clinical data from both trials. In the ACHIEVE trial, patients in the 5.4 mg/kg Q8W cohort had...
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Zacks via Yahoo Finance· 18 hours agoDyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoWALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases
